Evaluation of universal versus genotype-guided efavirenz dose reduction in pregnant women using population pharmacokinetic modelling | Zendy

Adeniyi Olagunju | Zendy; Alessandro Schipani | Zendy; Oluseye O. Bolaji | Zendy; Saye Khoo | Zendy; Andrew Owen | Zendy

Open Access

Evaluation of universal versus genotype-guided efavirenz dose reduction in pregnant women using population pharmacokinetic modelling

Author(s) -

Adeniyi Olagunju,

Alessandro Schipani,

Oluseye O. Bolaji,

Saye Khoo,

Andrew Owen

Publication year - 2017

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkx334

Subject(s) - efavirenz , pharmacokinetics , genotype , medicine , population , reduction (mathematics) , pharmacology , nonmem , obstetrics , human immunodeficiency virus (hiv) , biology , virology , mathematics , antiretroviral therapy , viral load , genetics , environmental health , gene , geometry

Lack of data on the pharmacokinetics of efavirenz in pregnant women at the 400 mg reduced dose currently prevents universal roll-out. Population pharmacokinetic modelling was used to explore pharmacokinetic endpoints at 200, 400 and 600 mg daily doses in pregnant women stratified by CYP2B6 metabolic status.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research